Please wait while the formulary information is being retrieved.
DEPO-PROVERA (MEDROXYPROGESTERONE ACETATE)
- Pregnancy contraception
- Medroxyprogesterone Intramuscular Syringe
- Medroxyprogesterone Im Syringe
- Depo-provera Intramuscular Syringe
- Depo-provera Im Syringe
- By Indication
150 mg/mL intramuscular syringe
- Inject 1 milliliter (150 mg) by intramuscular route every 3 months
medroxyprogesterone 150 mg/mL intramuscular syringe
- Inject 1 milliliter (150 mg) by intramuscular route every 3 months
150 mg/mL intramuscular syringe
- Inject 1 milliliter (150 mg) by intramuscular route every 3 months
150 mg/mL intramuscular syringe
- Inject 1 milliliter (150 mg) by intramuscular route every 3 months
150 mg/mL intramuscular syringe
- Inject 1 milliliter (150 mg) by intramuscular route every 3 months
Pregnancy contraception
- Inject 1 milliliter (150 mg) by intramuscular route every 3 months
- sodium tetradecyl sulfate
- Sotradecol
Contraindicated
- Aptivus
- artemether-lumefantrine
- atazanavir
- Atripla
- B cplx-C-St.Johnwrt-K.&S.ginsg
- Banzel
- boceprevir
- bosentan
- calcium-mag-B complex-D3-hrb61
- carbamazepine
- Carbatrol
- Cellcept
- Cellcept Intravenous
- chloramphenicol sod succinate
- clobazam
- Coartem
- Cold & Flu Fighter
- dabrafenib
- darunavir
- efavirenz
- efavirenz-emtricitabin-tenofov
- elvitegr-cobicist-emtric-tenof
- Epitol
- Equetro
- Fatigue Relief Complex
- fosamprenavir
- Grifulvin V
- Gris-peg (ultramicrosize)
- griseofulvin microsize
- griseofulvin ultramicrosize
- Incivek
- Invirase
- isoniazid-rifamp-pyrazinamide
- Kaletra
- Korlym
- Lexiva
- lopinavir-ritonavir
- mifepristone
- modafinil
- Mycobutin
- mycophenolate mofetil
- mycophenolate mofetil HCl
- mycophenolate sodium
- Myfortic
- nelfinavir
- nevirapine
- Norvir
- Norvir Soft Gelatin
- Onfi
- oxcarbazepine
- Oxtellar Xr
- Prezista
- Priftin
- Provigil
- Reyataz
- rifabutin
- Rifadin
- Rifamate
- rifampin
- rifampin-isoniazid
- rifapentine
- Rifater
- ritonavir
- rufinamide
- saquinavir mesylate
- St. John's wort
- Stribild
- Sustiva
- Tafinlar
- Tegretol
- Tegretol Xr
- telaprevir
- tipranavir
- Tracleer
- Trileptal
- Victrelis
- Viracept
- Viramune
- Viramune Xr
- vit C-St. John wort-elder-hb30
- Women's Complex
Severe
Moderate
- Adoxa
- aminophylline
- aprepitant
- Avidoxy
- demeclocycline
- Doryx
- Doxy-100
- doxycycline calcium
- doxycycline hyclate
- doxycycline monohydrate
- Dutoprol
- Elixophyllin
- Emend
- fosaprepitant
- Juxtapid
- lomitapide
- Lopressor
- Lopressor Hct
- metoprolol su-hydrochlorothiaz
- metoprolol succinate
- metoprolol ta-hydrochlorothiaz
- metoprolol tartrate
- Minocin
- minocycline
- Monodox
- Morgidox
- Oracea
- Solodyn
- tetracycline
- Theo-24
- Theochron
- theophylline
- theophylline in dextrose 5 %
- tigecycline
- Toprol Xl
- Tygacil
- Vibramycin
- Carcinoma of breast
- Cerebrovascular disorder
- Porphyria
- Predisposition to thrombosis
- Severe hepatic disease
- Thromboembolic disorder
- Thrombophlebitis
Contraindicated
- Osteopenia
- Osteoporosis
Severe
Moderate
- Breast fibroadenosis
- Depression
- Diabetes mellitus
- Edema
- Family history of malignant tumor of breast
- Hyperlipidemia
- Hypertension
- Weight gain
DEPO-PROVERA (MEDROXYPROGESTERONE ACETATE)
- Pregnancy contraception
- Abnormal vaginal bleeding
- Acute abdominal pain
- Dizziness
- General weakness
- Headache disorder
- Injection site sequelae
- Libido changes
- Menstrual disorder
- Nervousness
- Weight gain
More Frequent
Severe
Less Severe
- Depression
- Abdominal distension
- Acne vulgaris
- Alopecia
- Appetite changes
- Arthralgias
- Cramps in legs
- Dysmenorrhea
- Edema
- Fatigue
- Insomnia
- Mastalgia
- Nausea
- Skin rash
- Vaginal discharge
- Vaginitis
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Anaphylaxis
- Anemia
- Angioedema
- Carcinoma of cervix
- Deep venous thrombosis
- Disease of liver
- Endometrial hyperplasia
- Erythema multiforme
- Erythema nodosum
- Facial palsy
- Fracture
- Galactorrhea not associated with childbirth
- Hypercalcemia
- Hypercortisolism
- Neoplasm of breast
- Obstructive hyperbilirubinemia
- Osteopenia
- Osteoporosis
- Papilledema
- Pulmonary thromboembolism
- Rectal bleeding
- Retinal thrombosis
- Scleroderma
- Seizure disorder
- Thromboembolic disorder
- Thrombophlebitis
Less Severe
- Abnormal glucose tolerance
- Amenorrhea
- Body fluid retention
- Body odor
- Chloasma
- Drowsy
- Dry skin
- Erosion of cervix
- Euphoria
- Fever
- Flushing
- Hirsutism
- Hoarseness
- Increased libido
- Induration of skin
- Lactation deficiency
- Lipodystrophy
- Malaise
- Paresthesia
- Polydipsia
- Pruritus of skin
- Urticaria
Contraindicated
None
Severe Precaution
Medroxyprogesterone (Inj)
Not indicated before menarche. May affect bone development/density.
No safety and efficacy for use in endometrial or renal carcinoma. Reduces bone mineral density.
- 1 Day – 11 Years
- Not indicated before menarche. May affect bone development/density.
- No safety and efficacy for use in endometrial or renal carcinoma. Reduces bone mineral density.
- 11 Years – 18 Years
- Not indicated before menarche. May affect bone development/density.
- No safety and efficacy for use in endometrial or renal carcinoma. Reduces bone mineral density.
Management or Monitoring Precaution
None
Medroxyprogesterone
- Severity Level:
2
- Additional Notes: Available data suggest little or no known risk for developmental toxicity
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
Medroxyprogesterone
Human data indicate no known adverse effect on nursing infant
| General | Excretion Potential | Effect on Infant | Notes |
| No known risks; does not adversely affect lactation | Excreted | No adverse effect | Human data indicate no known adverse effect on nursing infant |
Contraindicated
None
Precaution Exists
Medroxyprogesterone Ac
Neuro/Psych-The Women's Health Initiative Memory Study demonstrated an increased relative risk (2.05, 95% CI) of probable dementia in the elderly when used in combination with estrogens.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | N | N | N | Y | N | N |
BEERS: N HEDIS: N STOPP: N
No Known Risk
None
- This medication may cause serious bone loss which may not return to normal after you stop using it. The risk of bone loss increases with longer use of this medication. This medication should not be used for longer than 2 years unless other birth control methods will not work for you.<br /><br />An important time when your bones continue to build up is during your teenage and young adult years. Use of this medication may increase the risk of weak/brittle bones (osteoporosis), which can lead to broken bones when you are older. Talk with your doctor about the risks and benefits of this medication and other birth control choices.<br /><br /> Do not use this medication if you smoke cigarettes/use tobacco and are over 35 years old. Smoking raises your risk of stroke, heart attack, blood clots, and high blood pressure from hormonal birth control (such as the pill, patch, ring). The risk of these serious problems increases with age and with the number of cigarettes you smoke. Do not smoke or use tobacco.
| Pregnancy contraception | |
| Z30 | Encounter for contraceptive management |
| Z30.01 | Encounter for initial prescription of contraceptives |
| Z30.011 | Encounter for initial prescription of contraceptive pills |
| Z30.013 | Encounter for initial prescription of injectable contraceptive |
| Z30.014 | Encounter for initial prescription of intrauterine contraceptive device |
| Z30.015 | Encounter for initial prescription of vaginal ring hormonal contraceptive |
| Z30.016 | Encounter for initial prescription of transdermal patch hormonal contraceptive device |
| Z30.017 | Encounter for initial prescription of implantable subdermal contraceptive |
| Z30.018 | Encounter for initial prescription of other contraceptives |
| Z30.019 | Encounter for initial prescription of contraceptives, unspecified |
| Z30.4 | Encounter for surveillance of contraceptives |
| Z30.40 | Encounter for surveillance of contraceptives, unspecified |
| Z30.41 | Encounter for surveillance of contraceptive pills |
| Z30.42 | Encounter for surveillance of injectable contraceptive |
| Z30.43 | Encounter for surveillance of intrauterine contraceptive device |
| Z30.430 | Encounter for insertion of intrauterine contraceptive device |
| Z30.431 | Encounter for routine checking of intrauterine contraceptive device |
| Z30.433 | Encounter for removal and reinsertion of intrauterine contraceptive device |
| Z30.44 | Encounter for surveillance of vaginal ring hormonal contraceptive device |
| Z30.45 | Encounter for surveillance of transdermal patch hormonal contraceptive device |
| Z30.46 | Encounter for surveillance of implantable subdermal contraceptive |
| Z30.49 | Encounter for surveillance of other contraceptives |
| Z30.8 | Encounter for other contraceptive management |
| Z30.9 | Encounter for contraceptive management, unspecified |
| Z79.3 | Long term (current) use of hormonal contraceptives |
| Z97.5 | Presence of (intrauterine) contraceptive device |
| 0-9 | A-Z |
|---|---|
| Z30 | Encounter for contraceptive management |
| Z30.01 | Encounter for initial prescription of contraceptives |
| Z30.011 | Encounter for initial prescription of contraceptive pills |
| Z30.013 | Encounter for initial prescription of injectable contraceptive |
| Z30.014 | Encounter for initial prescription of intrauterine contraceptive device |
| Z30.015 | Encounter for initial prescription of vaginal ring hormonal contraceptive |
| Z30.016 | Encounter for initial prescription of transdermal patch hormonal contraceptive device |
| Z30.017 | Encounter for initial prescription of implantable subdermal contraceptive |
| Z30.018 | Encounter for initial prescription of other contraceptives |
| Z30.019 | Encounter for initial prescription of contraceptives, unspecified |
| Z30.4 | Encounter for surveillance of contraceptives |
| Z30.40 | Encounter for surveillance of contraceptives, unspecified |
| Z30.41 | Encounter for surveillance of contraceptive pills |
| Z30.42 | Encounter for surveillance of injectable contraceptive |
| Z30.43 | Encounter for surveillance of intrauterine contraceptive device |
| Z30.430 | Encounter for insertion of intrauterine contraceptive device |
| Z30.431 | Encounter for routine checking of intrauterine contraceptive device |
| Z30.433 | Encounter for removal and reinsertion of intrauterine contraceptive device |
| Z30.44 | Encounter for surveillance of vaginal ring hormonal contraceptive device |
| Z30.45 | Encounter for surveillance of transdermal patch hormonal contraceptive device |
| Z30.46 | Encounter for surveillance of implantable subdermal contraceptive |
| Z30.49 | Encounter for surveillance of other contraceptives |
| Z30.8 | Encounter for other contraceptive management |
| Z30.9 | Encounter for contraceptive management, unspecified |
| Z79.3 | Long term (current) use of hormonal contraceptives |
| Z97.5 | Presence of (intrauterine) contraceptive device |
Formulary Reference Tool